EMA — authorised 21 September 2009
- Application: EMEA/H/C/000996
- Marketing authorisation holder: Gilead Sciences Ireland UC
- Local brand name: Cayston
- Indication: Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
- Status: approved